This translation is provided for general access and has no recorded medical-language review.
General medical information
This page provides only a general scope and sources for Information on Injection Lipolysis. Personal suitability, the product or device used, potential benefit, risks, alternatives and the option of no procedure require a physician examination.
Online content is not diagnosis, prescribing, personal risk assessment or a treatment plan. A reference list is not a clinical sign-off; product and device information must also be checked against current Turkish registration and instructions for use.
These sources are editorial starting points. Each may be limited to a specific product, method, indication or study population.
Source titles remain in their publication language. Localized notes summarize the interpretation boundary and do not replace the full text. This translation has no recorded clinical or medical-language review.
U.S. Food and Drug Administration · 2023 · Regulatory safety communication
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local product or device information.
Editorial source — not a clinical sign-off record
G. S. G. Inocêncio et al. · 2023 · Systematic review and meta-analysis
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local product or device information.
Editorial source — not a clinical sign-off record
S. M. Shridharani and M. L. Kennedy · 2024 · Systematic review
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local product or device information.
Editorial source — not a clinical sign-off record
Source-backed general information
The phrase fat-dissolving injection does not describe one treatment with the same content and use. Evidence, regulatory status and risks must be limited to the exact product, area and technique.
Kybella is a deoxycholic acid product defined in the US for adult submental fat; this does not establish Turkish authorisation, availability or other areas. Injection lipolysis is not one product; exact contents, authorised indication, anatomical area and technique must be verified.
Injections with unverified contents, manufacture or intended use have been linked to infection, ulcers, necrosis, scars and permanent deformity. Injection lipolysis is not one product; exact contents, authorised indication, anatomical area and technique must be verified.
Expected swelling differs from increasing pain, ulcer or colour change, pus, fever, marked asymmetry, swallowing difficulty or nerve symptoms. Injection lipolysis is not one product; exact contents, authorised indication, anatomical area and technique must be verified.
A study of one product for submental fat does not establish the same effect or safety in other facial or body areas. Injection lipolysis is not one product; exact contents, authorised indication, anatomical area and technique must be verified.
Using a dermal filler designed for a facial indication in the buttocks, breasts, between muscles or for large-volume body enhancement is not the same indication. FDA states that no dermal filler or injectable silicone is approved for large-scale body contouring and warns of embolism, infection, tissue death, permanent disfigurement and death.